share_log
Reuters ·  Mar 27 15:00
Merck Exec Says Hopes to Launch Subcutaneous Keytruda on Oct 1, Sees Peak Adoption About 18-24 Months After Approval - Interview
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 312

Recommended

Write a comment